权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of Pituitary Tumorigenesis

垂体肿瘤发生机制

基本信息

批准号：
8274839
负责人：
SHLOMO MELMED
金额：
$ 27.71万
依托单位：
CEDARS-SINAI MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-12-15 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8274839
关键词：
Accounting Adrenal Gland Hyperfunction Adrenal Glands Aneuploidy Benign Cell Culture Techniques Cell Cycle Cell Cycle Arrest Cell Cycle Checkpoint Cell Cycle Proteins Cell Cycle Regulation Cell Proliferation Cells Chromosomal Instability Clinical Corticotropin DNA Damage Development E2F1 gene Endocrine Syndrome Estrogens Failure Functional disorder Gene Deletion Gene Expression Genetic Genetic Models Genetic Transcription Genotype Gonadotropins Growth Growth Disorders Health Heterozygote Hormonal Hormones Human Hyperplasia In Vitro Infertility Intracranial Neoplasms Knock-in Mouse Link Malignant - descriptor Malignant Neoplasms Measures Mediating Mediator of activation protein Metabolic Mitosis Modeling Mus Neoplasms PTTG1 gene Pathogenesis Pathway interactions Penetrance Pituitary Diseases Pituitary Gland Pituitary Gland Adenoma Pituitary Neoplasms Pituitary carcinoma Pregnancy Prolactin Property Proteins Rattus Role S Phase Sister Chromatid Somatotropin Somatotropin-Releasing Hormone Structure Testing Thyroid Gland Tissues Transgenic Model Tumor Cell Line adenoma base cancer cell gonad function hormone regulation human PTTG1 protein improved inhibitor/antagonist insight mutant neoplastic cell premature protein expression protein function research study senescence tumor tumor growth tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Pituitary tumors account for 15% of intracranial neoplasms and are benign monoclonal neoplasms which may be clinically silent or secrete hormones including prolactin, growth hormone, ACTH, or rarely TSH or gonadotropins. These adenomas account for clinical infertility, growth disorders and hypercortisolism or metabolic dysfunctions associated with hypo-pituitarism. This proposal is aimed at exploring the role of disordered pituitary cell proliferation control in the pathogenesis of these invariably benign adenomas. In the first Aim, we will study mechanisms underlying pituitary aneuploidy, premature proliferative arrest (senescence), markers of cell proliferation and tumorigenesis in transgenic models of murine pituitary tumors (1GSU.PTTG and Rb heterozygotes). Mechanisms for both genetic and hormonally induced pituitary tumorigenesis will be studied in these genotypes and in pituitary cell cultures. In the second Aim we will study DNA damage, cellular markers of aneuploidy and senescent mediators in human pituitary tumors. In the third Aim we will study mechanisms for Rb/E2F induction of pituitary tumors by assessing E2F1 induction of Pttg transcription and protein expression in Rb mice, in mutant human cancer cells devoid of p53 or p21, as well as in human pituitary adenomas. Results of these experiments will enable further insights into the role of cell cycle control and growth constraint of experimental and human pituitary tumors, underlying their failure to progress to malignancy. The results will improve our understanding of clinical endocrine syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function.

描述（由申请方提供）：垂体瘤占颅内肿瘤的15%，是良性单克隆肿瘤，可能临床上无症状或分泌激素，包括催乳素、生长激素、ACTH或罕见的TSH或促性腺激素。这些腺瘤导致临床不孕、生长障碍和皮质醇增多症或与垂体功能减退相关的代谢功能障碍。该建议旨在探讨垂体细胞增殖控制紊乱在这些良性腺瘤发病机制中的作用。在第一个目标中，我们将在小鼠垂体瘤转基因模型（1GSU、PTTG和Rb杂合子）中研究垂体非整倍体、过早增殖停滞（衰老）、细胞增殖标记物和肿瘤发生的机制。将在这些基因型和垂体细胞培养中研究遗传和垂体诱导的垂体肿瘤发生机制。在第二个目标中，我们将研究人垂体瘤中的DNA损伤、非整倍体的细胞标志物和衰老介质。在第三个目标中，我们将研究Rb/E2 F诱导垂体瘤的机制，通过评估E2 F1诱导Rb小鼠，缺乏p53或p21的突变型人类癌细胞以及人类垂体腺瘤中的Pttg转录和蛋白表达。这些实验的结果将使进一步了解细胞周期的控制和实验和人类垂体瘤的生长限制的作用，潜在的他们未能进展到恶性肿瘤。这些结果将提高我们对与不孕症、生长障碍、皮质醇增多症或由于垂体功能丧失导致的肾上腺、甲状腺和性腺衰竭相关的临床内分泌综合征的理解。

项目成果

期刊论文数量（71）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

DOI：
10.1172/jci19933
发表时间：
2004-08
期刊：
The Journal of clinical investigation
影响因子：
0
作者：
R. Murray;Kiwon Kim;S. Ren;M. Chelly;Y. Umehara;S. Melmed
通讯作者：
R. Murray;Kiwon Kim;S. Ren;M. Chelly;Y. Umehara;S. Melmed

Pituitary somatostatin receptor signaling.

DOI：
10.1016/j.tem.2009.12.003
发表时间：
2010-03
期刊：
TRENDS IN ENDOCRINOLOGY AND METABOLISM
影响因子：
10.9
作者：
Ben-Shlomo, Anat;Melmed, Shlomo
通讯作者：
Melmed, Shlomo

E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

DOI：
10.1210/me.2009-0161
发表时间：
2009-12
期刊：
Molecular endocrinology
影响因子：
0
作者：
Cuiqi Zhou;K. Wawrowsky;S. Bannykh;S. Gutman;S. Melmed
通讯作者：
Cuiqi Zhou;K. Wawrowsky;S. Bannykh;S. Gutman;S. Melmed

Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy.

雌二醇部分概括了小鼠垂体细胞周期对妊娠的反应。

DOI：
10.1210/en.2012-1492
发表时间：
2012
期刊：
Endocrinology
影响因子：
4.8
作者：
Toledano,Yoel;Zonis,Svetlana;Ren,Song-Guang;Wawrowsky,Kolja;Chesnokova,Vera;Melmed,Shlomo
通讯作者：
Melmed,Shlomo

Pituitary tumor registry: a novel clinical resource.

垂体肿瘤登记处：一种新颖的临床资源。